北京城建(600266.SH):9870.9萬元競得安徽黃山市兩宗宅地
格隆匯12月20日丨北京城建(600266.SH)公佈,公司全資子公司北京城建黃山投資發展有限公司參加安徽省黃山市黃山區譚家橋鎮南部組團B-13-20、B-13-22地塊國有建設用地使用權競買。項目位於黃山市黃山區譚家橋鎮,總建設用地面積50621.2㎡,規劃建築面積60745.44㎡。
2019年12月20日公司收到《成交確認書》,北京城建黃山投資發展有限公司以9870.9萬元的價格競得安徽省黃山市黃山區譚家橋鎮南部組團B-13-20(黃自然掛2019-19號)、B-13-22(黃自然掛2019-20號)地塊國有建設用地使用權,用地性質為二類居住用地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.